Abstract:
This Article considers how tax is poised to respond to CRISPR [Clustered Regularly Interspaced Short Palindromic Repeats] and similar emerging medical technologies with both therapeutic and so called enhancement applications. Doing so exposes gaps in current tax law as applied to the body and biotechnologies.